Titan Pharmaceuticals Q2 Teleconference
Tuesday, August 17 2:00-2:45pm EST (11:00-11:45am PST)
EVENT/REGISTRATION PAGE URL FOR THE WEBCAST IS:
http://www.videonewswire.com/event.asp?id=71858
Participant Dial In (Toll Free): 1-800-860-2442
International Dial In: 1-412-858-4600
-----------------------------------------------------------
About Titan
Titan Pharmaceuticals, Inc. is a biopharmaceutical company with valuable assets in the CNS (central nervous system) area.
Fanapt™ (iloperidone)
On May 6, 2009 Fanapt™, an atypical antipsychotic drug, was granted marketing approval by the US Food & Drug Administration for the treatment of adult patients with schizophrenia. Titan is entitled to receive 8-10% royalties on global net sales of Fanapt™, which are expected to commence by the end of 2009. The global sales of atypical antipsychotic products exceeds $20 billion per year.
Probuphine®
Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following a single treatment. This product is in Phase 3 development and has already demonstrated strong positive results in a controlled Phase 3 study for the treatment of opioid addiction. Titan continues to look for partners and other sources of funds to complete this development program.
In furtherance of the Company's efforts to conserve capital, in December 2008 the Company filed with the Securities and Exchange Commission a Form 25 to voluntarily delist from the American Stock Exchange and a Form 15 to voluntarily suspend its reporting obligations under the Securities Exchange Act of 1934, as amended. The Company's common stock is traded on the Pink OTC Markets ([TTNP.PK] www.pinksheets.com)quotations system. For further information please contact
Sunil Bhonsle, President at:
PRESS RELEASES
SOUTH SAN FRANCISCO, CA August 16, 2010 — Titan Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010.
Total revenues for the second quarter of 2010 were $1.34 million, consisting primarily of grant and royalty revenues. Grant revenue from the National Institutes of Health (NIH) in support of the Phase 3 clinical study of Probuphine® was approximately $1.29 million, while royalty revenue received from Novartis on net sales of Fanapt® was approximately $ 55,000.
SOUTH SAN FRANCISCO, CA August 3, 2010 — Titan Pharmaceuticals, Inc. today announced that patient enrollment is more than 60% complete in the confirmatory Phase 3 clinical study of Probuphine for the treatment of opioid addiction, and the study is expected to complete enrollment by early fourth quarter of this year, which is almost three months ahead of schedule.
SOUTH SAN FRANCISCO, CA July 26, 2010 — Titan Pharmaceuticals, Inc. today announced that the National Institutes of Health (NIH) has awarded the company a grant under the Small Business Innovation Research (SBIR) program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson's disease.
SOUTH SAN FRANCISCO, CA July 23, 2010 — Titan Pharmaceuticals, Inc. today reported that the company expects to receive a royalty payment of approximately $55,000 on second quarter 2010 sales of Fanapt (iloperidone) of approximately $693,000.
SOUTH SAN FRANCISCO, CA June 16, 2010 — Titan Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued patent number 7,736,665 covering Probuphine for the treatment of opiate addiction. Titan is the assignee of this patent which claims a method for treating opiate addiction with a subcutaneously implanted device comprising buprenorphine and ethylene vinyl acetate, a biocompatible copolymer that releases buprenorphine continuously for extended periods of time. This patent, which also includes certain additional claims covering the composition and dimensions of the device, will expire in June 2023 excluding any patent term adjustment which is expected to add several months to the life of the patent.
SOUTH SAN FRANCISCO, CA May 17, 2010 — Titan Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010.
Total revenues for the first quarter of 2010 were $2.4 million consisting primarily of royalty and grant revenues. The first quarter marked a key milestone for Titan with the commercial launch of Fanapt™ in the U.S. by Novartis, which generated $1.7 million in royalty revenue for Titan. Grant revenue from the National Institutes of Health (NIH) in support of the Phase 3 clinical study of Probuphine® was $0.7 million.
SOUTH SAN FRANCISCO, CA April 27, 2010 — Titan Pharmaceuticals, Inc. today announced that the Securities and Exchange Commission (SEC) has completed the review of Titan's Form 10 for the re-registration of the company's securities and resumption of its reporting obligations under the Securities Exchange Act of 1934.
SOUTH SAN FRANCISCO, CA April 21, 2010 — Titan Pharmaceuticals, Inc. today confirmed that the company expects to receive a payment of approximately $1.6 million by May 15, 2010 as the royalty on the first quarter 2010 sales of Fanapt™ (iloperidone), a drug for the treatment of schizophrenia launched in the US by Novartis Pharma AG in January 2010.
SOUTH SAN FRANCISCO, CA March 30, 2010 — Titan Pharmaceuticals, Inc. today announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine® in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients).